| 1. | EXECUTIVE SUMMARY |
| 1.1. | Scope of the Report |
| 1.2. | Factors Encouraging the Rise of Digital Health and Remote Patient Monitoring |
| 1.3. | Benefits of Remote Patient Monitoring |
| 1.4. | Components of a Remote Monitoring System |
| 1.5. | Common Measurements and Applications |
| 1.6. | Types of RPM Companies |
| 1.7. | Vital Sign Monitoring In and Out of the Hospital |
| 1.8. | RPM of Cardiovascular Diseases |
| 1.9. | RPM for Hypertension (High Blood Pressure) |
| 1.10. | RPM for Atrial Fibrillation & Other Arrythmias |
| 1.11. | RPM for Heart Failure |
| 1.12. | RPM of Diabetes and Prediabetes |
| 1.13. | RPM of Respiratory Conditions |
| 1.14. | RPM Technologies for Other Chronic Diseases |
| 1.15. | RPM in Clinical Trials |
| 1.16. | Remote Monitoring of the Elderly |
| 1.17. | Wearables for Health Insurance |
| 1.18. | Market Forecast 2023-2033: RPM Devices |
| 2. | INTRODUCTION |
| 2.1. | Scope of the Report |
| 2.2. | Factors Encouraging the Rise of Digital Health and Remote Patient Monitoring |
| 2.3. | Changing Demographics Require Healthcare Reforms |
| 2.4. | Global Healthcare Spending is Rising |
| 2.5. | Why Telemedicine? |
| 2.6. | Driving the Uptake of Telemedicine |
| 2.7. | Benefits of Remote Patient Monitoring |
| 2.8. | Components of a Remote Monitoring System |
| 2.9. | Common Measurements and Applications |
| 2.10. | The Impact of COVID-19 on Digital Health |
| 2.11. | Shifts Towards Value-Based Care |
| 2.12. | Positive Trends in Reimbursement Continues in the US |
| 2.13. | From Connected to Wearable |
| 2.14. | Broadband Access is a Determinant of Health |
| 2.15. | Design Challenges for RPM |
| 3. | REMOTE PATIENT MONITORING |
| 3.1. | Overview |
| 3.1.1. | Types of RPM Companies |
| 3.1.2. | Teladoc Health |
| 3.1.3. | Livongo by Teladoc Health |
| 3.1.4. | Amwell |
| 3.1.5. | MDLive |
| 3.1.6. | Omada Health |
| 3.1.7. | Optimize Health |
| 3.1.8. | Market Outlook |
| 3.2. | Vital Sign Monitoring - Inpatient and Outpatient |
| 3.2.1. | Introduction |
| 3.2.2. | Inpatient Monitoring: Background |
| 3.2.3. | RPM in the Hospital |
| 3.2.4. | The Case for Removing the Wires |
| 3.2.5. | RPM in the Hospital: Form Factors |
| 3.2.6. | Parameter Comparison |
| 3.2.7. | The Case Against RPM |
| 3.2.8. | Vital Sign Monitoring at Home |
| 3.2.9. | Post-Discharge Monitoring |
| 3.2.10. | COVID-19 at Home |
| 3.2.11. | Cancer |
| 3.2.12. | Cancer: Symptom Monitoring |
| 3.2.13. | Cancer: Performance Status |
| 3.2.14. | Deployment Challenges for Monitoring Devices |
| 3.2.15. | Summary and Outlook |
| 3.2.16. | Emerging Options for General Vital Sign Monitoring |
| 3.2.17. | Summary |
| 3.2.18. | Vital Sign Monitoring: Key Companies |
| 3.2.19. | Electronic Skin Patches |
| 3.2.20. | Philips |
| 3.2.21. | The Surgical Company (formerly Sensium) |
| 3.2.22. | BioIntelliSense |
| 3.2.23. | VitalConnect |
| 3.2.24. | Vivalink (VivaLNK) |
| 3.2.25. | Non-Contact Monitoring Technologies |
| 3.2.26. | EarlySense |
| 3.2.27. | EarlySense |
| 3.2.28. | Xandar Kardian |
| 3.2.29. | Oxehealth |
| 3.3. | Cardiovascular Diseases - Hypertension, Atrial Fibrillation, and Heart Failure |
| 3.3.1. | Background |
| 3.3.2. | Remote Patient Monitoring in Cardiovascular Diseases |
| 3.3.3. | Technology Summary |
| 3.3.4. | Electrocardiography (ECG, or EKG) |
| 3.3.5. | Photoplethysmography (PPG) |
| 3.3.6. | Example Charts |
| 3.4. | Hypertension |
| 3.4.1. | Background |
| 3.4.2. | Classification |
| 3.4.3. | Management |
| 3.4.4. | Remote Patient Monitoring |
| 3.4.5. | Oscillometric Method |
| 3.4.6. | Oscillometric Devices |
| 3.4.7. | Omron Healthcare |
| 3.4.8. | Omron Healthcare: HeartGuide |
| 3.4.9. | Omron Healthcare: VitalSight |
| 3.4.10. | Withings |
| 3.4.11. | Optical Measurement Techniques - Cuff-Less Blood Pressure Monitoring |
| 3.4.12. | Pulse Arrival Time, Pulse Transit Time, and Pulse Wave Velocity |
| 3.4.13. | Asus: VivoWatch BP, VivoWatch SP |
| 3.4.14. | Asus: VivoWatch SP |
| 3.4.15. | Pulse Wave Analysis |
| 3.4.16. | Pulse Wave Analysis: Methods |
| 3.4.17. | Aktiia: Aktiia Bracelet |
| 3.4.18. | Biospectal |
| 3.4.19. | Valencell: Cuffless Blood Pressure |
| 3.4.20. | Summary and Outlook |
| 3.5. | Atrial Fibrillation and Other Arrythmias |
| 3.5.1. | Background |
| 3.5.2. | (Early) Detection of Atrial Fibrillation |
| 3.5.3. | Detection and Diagnosis of Atrial Fibrillation and other Arrhythmias |
| 3.5.4. | Atrial Fibrillation: Screening & Detection |
| 3.5.5. | AliveCor |
| 3.5.6. | AliveCor: KardiaMobile |
| 3.5.7. | Qompium: FibriCheck |
| 3.5.8. | Smartwatches: Apple, Fitbit, Samsung |
| 3.5.9. | Smartwatches: User Demographics vs Cardiovascular Conditions |
| 3.5.10. | Atrial Fibrillation: Diagnosis |
| 3.5.11. | Progress Towards Ambulatory Cardiac Monitoring |
| 3.5.12. | Electronic Skin Patches |
| 3.5.13. | Electronic Skin Patches |
| 3.5.14. | Ambulatory Heart Rhythm Monitoring: Players |
| 3.5.15. | Philips (BioTelemetry) |
| 3.5.16. | iRhythm |
| 3.5.17. | Insertable Cardiac Monitors |
| 3.5.18. | Atrial Fibrillation: Treatment |
| 3.5.19. | Artificial Pacemakers |
| 3.5.20. | Artificial Pacemakers and RPM |
| 3.5.21. | Artificial Pacemakers and RPM: Platforms |
| 3.5.22. | Artificial Pacemakers and RPM: Apps |
| 3.5.23. | Summary and Outlook |
| 3.6. | Heart Failure |
| 3.6.1. | Background |
| 3.6.2. | Management and Challenges to RPM |
| 3.6.3. | Management: Lack of RPM Technologies |
| 3.6.4. | Remote Patient Monitoring |
| 3.6.5. | Management: Disease Progression |
| 3.6.6. | Abbott: CardioMEMS HF System |
| 3.6.7. | Abbott: CardioMEMS HF System |
| 3.6.8. | Non-Invasive Monitoring |
| 3.6.9. | toSense: CoVa 2 |
| 3.6.10. | BodiGuide |
| 3.6.11. | Sensible Medical: ReDS for Home |
| 3.6.12. | Zoll Medical: Heart Failure Management System (HFMS), µCor |
| 3.6.13. | Chronolife: KeeSense |
| 3.6.14. | Cardiac Resynchronization Therapy with Defibrillator and Implantable Cardioverter Defibrillator |
| 3.6.15. | Summary and Outlook |
| 3.7. | Diabetes - Type 1, Type 2, and Prediabetes |
| 3.7.1. | Background |
| 3.7.2. | Delivering insulin is a critical part of diabetes management |
| 3.7.3. | Management: Self-Management Devices |
| 3.7.4. | Management: Self-Management Devices |
| 3.7.5. | Remote Patient Monitoring |
| 3.7.6. | Digital Health Programs |
| 3.7.7. | Digital Health Programs: Evidence for Type 2 Diabetes |
| 3.7.8. | Digital Health: Diabetes Apps |
| 3.7.9. | Glooko |
| 3.7.10. | Diabetes Management Ecosystem |
| 3.7.11. | Continuous Glucose Monitoring in Hospitals |
| 3.7.12. | Summary and Outlook |
| 3.7.13. | Glucose Monitoring Devices |
| 3.7.14. | Background |
| 3.7.15. | Glucose Monitoring Devices |
| 3.7.16. | Anatomy of a Glucose Test Strip |
| 3.7.17. | Continuous Glucose Monitoring (CGM) |
| 3.7.18. | Anatomy of a Typical CGM Device |
| 3.7.19. | CGM: Technology |
| 3.7.20. | CGM: Sensor Chemistry |
| 3.7.21. | CGM: Overview of key players |
| 3.7.22. | Abbott: Freestyle® Libre |
| 3.7.23. | Non-Invasive Glucose Monitoring |
| 3.7.24. | Non-Invasive Glucose Monitoring: Analytes |
| 3.7.25. | When will non-invasive glucose monitoring be commercialised? |
| 3.7.26. | Insulin Delivery Devices |
| 3.7.27. | Background |
| 3.7.28. | Insulin Delivery Devices |
| 3.7.29. | Insulin Pens |
| 3.7.30. | Insulin Pumps |
| 3.7.31. | Insulin pump players and market share |
| 3.7.32. | Hybrid Closed Loop Systems |
| 3.7.33. | Medtronic: SmartGuard Auto Mode |
| 3.7.34. | Insulin Pump Technology Roadmap |
| 3.7.35. | Closed-loop: software |
| 3.8. | Respiratory Diseases - Chronic Obstructive Pulmonary Disorder and Asthma |
| 3.8.1. | Background |
| 3.8.2. | Chronic Obstructive Pulmonary Disorder |
| 3.8.3. | Asthma |
| 3.8.4. | Remote Patient Monitoring |
| 3.8.5. | Inhalers |
| 3.8.6. | Smart Inhalers: Companies |
| 3.8.7. | Propeller Health |
| 3.8.8. | Propeller & Novartis in Asthma Care |
| 3.8.9. | Teva: Digihaler |
| 3.8.10. | BreezoMeter |
| 3.8.11. | Spirometers |
| 3.8.12. | NuvoAir |
| 3.8.13. | Other Respiratory Monitoring |
| 3.8.14. | Respiri |
| 3.8.15. | Health Care Originals |
| 3.8.16. | Spire Health |
| 3.8.17. | Summary and Outlook |
| 3.9. | Other Remote Patient Monitoring Applications |
| 3.9.1. | Other Remote Patient Monitoring Applications |
| 3.9.2. | Parkinson's Disease |
| 3.9.3. | Parkinson's Disease: The Need for More Data |
| 3.9.4. | Parkinson's Disease: Movement Sensors |
| 3.9.5. | Global Kinetics: PKG |
| 3.9.6. | Rune Labs: StrivePD |
| 3.9.7. | Rheumatoid Arthritis & Other Autoimmune Diseases |
| 3.9.8. | Multiple Sclerosis |
| 3.9.9. | Musculoskeletal Conditions |
| 3.9.10. | MSK: Digital Physical Therapy / Remote Rehabilitation |
| 3.9.11. | Zimmer Biomet: Persona IQ |
| 3.9.12. | Summary and Outlook |
| 3.10. | Remote Patient Monitoring in Clinical Trials |
| 3.10.1. | Clinical Trials |
| 3.10.2. | RPM in Clinical Trials |
| 3.10.3. | Wearables in Clinical Trials: Adoption Timeline |
| 3.10.4. | CTTI and DiMe |
| 3.10.5. | CTTI Framework of Specifications |
| 3.10.6. | Digital Endpoints |
| 3.10.7. | Digital Endpoints: Importance to Alzheimer's Disease Research |
| 3.10.8. | CTTI Database: Condition analysis |
| 3.10.9. | CTTI Database: Sensor type |
| 3.10.10. | Barriers to Adoption for Wearable RPM |
| 3.10.11. | Barriers to Adoption for Wearable RPM (con't) |
| 3.10.12. | Virtual and Decentralized Trials |
| 3.10.13. | COVID-19 Vaccine Trials |
| 3.10.14. | Sensors used in Decentralized Trials |
| 3.10.15. | Is FDA clearance necessary for success? |
| 3.10.16. | Summary and Outlook |
| 3.11. | Monitoring the Elderly |
| 3.11.1. | Background |
| 3.11.2. | Remote Monitoring Technologies for the Elderly |
| 3.11.3. | Fall Detection |
| 3.11.4. | Fall Detection: Examples |
| 3.11.5. | Fall Detection: Examples |
| 3.11.6. | Health Tracking |
| 3.11.7. | Canary Care |
| 3.11.8. | Somatix: SafeBeing |
| 3.11.9. | Diaper Monitoring |
| 3.11.10. | Technologies for Medical Adherence |
| 3.11.11. | Baby Monitoring |
| 3.11.12. | Summary and Outlook |
| 3.12. | Fitness and Wellness Wearables for Health Insurance |
| 3.12.1. | Fitness and Wellness |
| 3.12.2. | Health Insurance and Corporate Wellness |
| 3.12.3. | Vitality: Background |
| 3.12.4. | Vitality: Device Partners |
| 3.12.5. | UnitedHealth Group: Background |
| 3.12.6. | UnitedHealthcare: Target biometrics and device adoption |
| 3.12.7. | Biomarker Usage in Health Insurance: Timeline |
| 3.12.8. | Outlook for New Biomarkers? |
| 3.12.9. | Barriers to Adoption |
| 3.12.10. | Summary and Outlook |
| 4. | MARKET FORECASTS |
| 4.1. | Overview |
| 4.2. | Methodology |
| 4.3. | Market Forecast 2023-2033: RPM Devices |
| 4.4. | Market Forecast 2023-2033: General Vital Sign Monitoring |
| 4.5. | Market Forecast 2023-2033: Skin Patches for Inpatient and Outpatient Monitoring |
| 4.6. | Market Forecast 2023-2033: Non-Contact Vital Sign Monitoring Devices |
| 4.7. | Market Forecast 2023-2033: Wrist-Based Wearables |
| 4.8. | Market Forecast 2023-2033: Blood Pressure Cuffs and Home Use Pulse Oximeters |
| 4.9. | Market Forecast 2023-2033: Smart Clothing |
| 4.10. | Market Forecast 2023-2033: Skin Patches for Heart Rhythm Monitoring |
| 4.11. | Market Forecast 2023-2033: Diabetes Monitoring |
| 4.12. | Market Forecast 2023-2033: Continuous Glucose Monitors, Glucometers, and Test Strips |
| 4.13. | Market Forecast 2023-2033: Insulin Pens and Pumps |
| 4.14. | Market Forecast 2023-2033: Smart Respiratory Devices |